Immunomonitoring

The Immunomonitoring core facility has contributed to the publication of the following scientific articles.

^{The MNK1/2-eIF4E axis supports immune suppression and metastatic in postpartum breast cancer Guo Q, Bartish M, Gonçalves C, Huang F, Smith-Voudouris J, Krisna SS, Preston SEJ, Emond A, Li VZ, Duerr CU, Gui Y, Cleret-Buhot A, Thébault P, Lefrère H, Lenaerts L, Plourde D, Su J, Mindt BC, Hewgill SA, Cotechini T, Hindmarch CCT, Yang W, Khoury E, Zhan Y, Narykina V, Wei Y, Floris  G, Basik  M, Amant F, Quail DF, Lapointe R, Fritz JH, Del Rincon SV, Miller WH Jr. Cancer Research 2021.}

^{Exploring cannabidiol effects on inflammatory markers in individuals with cocain use disorder: a randomized controlled trial. Morissette F, Mongeau-Pérusse V, Rizkallah E, Thébault P, Lepage  S, Brissette S, Bruneau J, Dubreucq S, Stip E, Cailhier  JF, Jutras-Aswad D. Neuropsychopharmacology 2021.}

^{Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Esfahani K, Al-Aubodah TA, Thébault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Nature Communications 2019.}

^{Alemtuzumab for PD-1 induced myocarditis. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson N, Miller W. New England Journal of Medicine 2019.}

^{Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr. Journal of ImmunoTherapy of Cancer 2017.}